Standalone audited financial results of the company for the quarter and year ended on 31 March 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genomic Valley Biotech reported a net loss of Rs. 8.35 lakh for FY26, a sharp decline from a profit of Rs. 3.03 lakh in FY25. Total revenue slightly decreased from Rs. 26.75 lakh to Rs. 26.36 lakh year-on-year. The company posted a loss before exceptional items of Rs. 28.42 lakh. The statutory auditor, Andros & Co., issued an unmodified opinion, confirming clean financials with no going concern issues. The board also approved appointment of Mr. Navjyoti Kumar Jha as Internal Auditor for FY27.
The company swung to a loss in FY26, which is a negative signal for shareholders. However, the clean audit opinion without qualifications provides some comfort regarding financial reporting integrity.